发明授权
US08202850B2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
有权
通过最优化5'末端调节基于寡核苷酸的化合物的免疫刺激性质
- 专利标题： Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
- 专利标题（中）： 通过最优化5'末端调节基于寡核苷酸的化合物的免疫刺激性质
-
申请号： US12957925申请日： 2010-12-01
-
公开(公告)号： US08202850B2公开(公告)日： 2012-06-19
- 发明人: Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
- 申请人： Sudhir Agrawal , Ekambar R. Kandimalla , Dong Yu , Lakshmi Bhagat
- 申请人地址： US MA Cambridge
- 专利权人： Idera Pharmaceuticals, Inc.
- 当前专利权人： Idera Pharmaceuticals, Inc.
- 当前专利权人地址： US MA Cambridge
- 代理机构： Wood, Phillips, Katz, Clark & Mortimer
- 主分类号： C07H21/04
- IPC分类号： C07H21/04 ; C07H21/02 ; A01N43/04 ; A61K39/00 ; A61K39/38 ; A61K45/00 ; A61K47/00 ; A61K31/70
摘要：
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
公开/授权文献
信息查询
